DUBLIN–(BUSINESS WIRE)–The “Oligonucleotide Synthesis Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering.
The oligonucleotide synthesis market is expected to register a CAGR of 12.3% during the forecast period 2022-2027
The growth of the oligonucleotide synthesis market is due to the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.
The usage of synthetic oligonucleotides has been increasing rapidly over the past decade, owing to several benefits offered by molecular diagnostics and growing clinical applications. The nucleic acid application techniques are the reference methods. They are very useful for carrying out molecular diagnosis in several diseases, like the detection of infectious diseases, such as hepatitis.
For instance, In January 2020, the Department of Biotechnology (DBT) initiated the “Genome India Project” (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some focus areas of this project are precision health, rare genetic disorders, mutation spectrum of genetic & complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research.
In addition to this, in February 2021, the Centre for Process Innovation (CPI) launched a project in the Medicines Manufacturing Innovation Centre in the United Kingdom. This project aims to revolutionize the manufacturing of oligonucleotides through a collaboration with AstraZeneca, Exactmer, Novartis, and the United Kingdom Research & Innovation.
Inclisiran, a small interfering RNA used in the treatment of atherosclerotic cardiovascular disease (ASCVD), would be the first medicine produced at a commercial scale as a result of this collaboration. Synthetic oligonucleotides also have significant clinical applications, primarily for the detection of autoimmune antibodies. There have been consistent developments in synthetic biology over the past few years, where synthetic oligonucleotides were used to develop assays for the detection of anti-double-stranded DNAs. Thus, all these factors are responsible for the growth of the oligonucleotide synthesis market.
However, there have been various instances in the past wherein, due to high complexities such as severe side effects, many drugs have been withdrawn or have failed in clinical trial phases. Such instances could become recurrent and may restrain market growth to a certain extent.
Key Market Trends
The Therapeutic Application Segment is Expected to Grow during the Forecast Period
Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. The increasing number of Food and Drug Administration-approved drugs and a rich clinical pipeline of oligonucleotide-based drugs are factors expected to drive the growth of these therapeutics in the coming years.
The increasing applications of oligos as therapeutic agents (such as antisense oligos and siRNA) used in treating neurological, infectious, and rare genetic disorders are expected to drive market growth.
Oligonucleotide therapeutics is an emerging drug modality, which consists of modified or unmodified short nucleic acid molecules, and includes antisense oligonucleotides (ASOs), small interfering RNA (siRNAs), microRNA (miRNAs), aptamers, and DNAzymes. For instance, as per the study published by the National Library of Medicine in March 2021, titled ‘Recent Advances in Oligonucleotide Therapeutics in Oncology’, currently, oligonucleotide therapeutics investigated in clinical trials include ASOs, siRNAs, miRNAs, aptamers, and DNAzymes. Their mechanisms of action differ, resulting in the correction of either abnormal expression or splicing patterns.
In addition to this, in March 2020, viltolarsen, developed by Japanese companies, was approved as a treatment for Duchenne muscular dystrophy. Moreover, in June 2022, GSK plc presented promising interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks’ treatment in people with chronic hepatitis B (CHB). Such investigations are expected to boost the segment’s growth in the years to come.
Nucleic acid-based therapeutics that regulate gene expression have been developed for clinical use at a steady pace for several decades, but in recent years the field has been accelerating and hence have, contributed to the segment’s strong growth.
Market Dynamics
Market Drivers
- Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies
- The Use of Synthesized Oligonucleotides in Molecular Diagnostics and Clinical Applications
Market Restraints
- High Treatment Cost of Oligonucleotides
- Lack of Skilled Professionals and Research Support in Undeveloped Countries
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value – USD million)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Companies Mentioned
- Agilent Technologies
- Thermo Fisher Scientific
- Merck KGaA
- Danaher Corporation
- Bio-Synthesis Inc.
- Eurofins Scientific
- Kaneka Corporation (Eurogentec)
- GenScript
- LGC Limited (LGC Biosearch Technologies)
- Maravai Life Sciences
- Biogen
- Sarepta Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jzzw3u
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900